Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain DVAX message board posts where the ticker symbol DVAX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest DVAX SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 1.01 and 2.03
Acc-no: 0001193125-19-195635 (34 Act)  Size: 19 KB
2019-07-17 001-34207
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001319244-19-000060 (34 Act)  Size: 97 KB
2019-07-09 005-80035
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-038496 Size: 5 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-037785 Size: 5 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-037784 Size: 5 KB
8-K  Documents Current report, item 5.02
Acc-no: 0001564590-19-021785 (34 Act)  Size: 31 KB
2019-06-05 001-34207
8-K/A  Documents [Amend] Current report, item 5.02
Acc-no: 0001564590-19-021783 (34 Act)  Size: 26 KB
2019-06-05 001-34207
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-034568 Size: 6 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-034566 Size: 7 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-034564 Size: 7 KB
More DVAX SEC Filings

Related news from
Sun, 14 Jul 2019
23:03:00 +0000
3 Biotech Stocks That Could Double Your Money
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
Thu, 11 Jul 2019
15:55:02 +0000
Dynavax: Last Chance to Make Good
The battered biotech is in the hot seat
Thu, 04 Jul 2019
15:39:00 +0000
Why Dynavax Technologies' Stock Tanked in June
Dynavax has been locked into a long-term downward trend, but the bottom might be near. Here's why.
Thu, 27 Jun 2019
15:19:29 +0000
Here’s What Hedge Funds Think About Dynavax Technologies Corporation (DVAX)
Is Dynavax Technologies Corporation (NASDAQ:DVAX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]
Mon, 03 Jun 2019
20:05:00 +0000
Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference  
BERKELEY, Calif., June 03, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim.
Mon, 03 Jun 2019
18:15:00 +0000
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
Progression Free Survival (PFS) rate of 18-months in 72% of patientsClinical efficacy in patients with immunologically cold tumor at baselineThe combination of SD-101 and.
Sat, 01 Jun 2019
18:15:00 +0000
Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
24% overall response rate in ITT populationResponses were observed in SD-101 injected and non-injected lesions The combination of SD-101 and pembrolizumab was well-tolerated.
Mon, 27 May 2019
09:00:09 +0000
Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
Sun, 26 May 2019
21:03:35 +0000
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...
Fri, 24 May 2019
22:10:00 +0000
Here's Why Dynavax Technologies Is Tumbling
The company's latest restructuring announcement isn't sitting well with investors.
Fri, 24 May 2019
21:41:13 +0000
East Bay biotech pivoted to cancer, found new space — now CEO is leaving, 82 jobs are cut
The company is returning its focus to its easier-to-take hepatitis B vaccine and other vaccine work.
Fri, 24 May 2019
11:44:48 +0000
The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
Thu, 23 May 2019
21:25:00 +0000
Dynavax announces layoffs, CEO retirement
Dynavax Technologies Corp. said late Thursday it will focus on its vaccine business and on its first commercial product, a hepatitis B vaccine, looking to unwind its immuno-oncology business. The company will also lay off workers and trim operations to focus on the vaccine's commercialization. "Following a comprehensive analysis of our assets, strengths and opportunities, we have determined we should focus our resources on our approved vaccine, HEPLISAV-B, which, as the only two-dose hepatitis B vaccine, is gaining market share and is well positioned to become the new standard of care in the U.S," Chief Executive Eddie Gray said. In the same press release, Gray said that the restructuring was "the optimal time" for his retirement, effective Aug. 1. The company's board of directors has created an interim office of the president and has appointed David Novack and Ryan Spencer, two senior vice presidents, as co-presidents effective immediately. Shares of Dynavax, halted earlier in the extended session, fell more than 5% when they resumed trading. The shares ended the regular session 0.2% lower.
Thu, 23 May 2019
20:45:00 +0000
Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business
Dynavax Technologies Corporation (DVAX), today announced a strategic restructuring to prioritize its vaccine business by focusing on the company’s first commercial product HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]. As part of the restructuring, the company will explore strategic alternatives for its immuno-oncology portfolio and will reduce the company’s workforce and operations to focus resources on HEPLISAV-B commercialization.
Tue, 21 May 2019
15:14:54 +0000
Could The Dynavax Technologies Corporation (NASDAQ:DVAX) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Dynavax Technologies Corporation (NASDAQ:DVAX) have power over the company. Large...
Mon, 20 May 2019
04:29:01 +0000
Edited Transcript of DVAX earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Dynavax Technologies Corp Earnings Call
Fri, 10 May 2019
13:14:00 +0000
Hopeful Signs for These 2 Small Biotech Stocks
A non-biotech investor would think FDA approval is the biggest hurdle for most small biotech companies and would be rewarded by the market. This is why so many small biotech stocks frequently decline in the quarters following the initial euphoria of FDA approval. This is why initial drug rollouts are usually slower and consume more cash that investors expect after the FDA green light is granted.
Thu, 09 May 2019
18:08:00 +0000
Why Dynavax Technologies Stock Is Soaring Today
Heplisav-B's commercial launch is starting to ramp up.
Thu, 09 May 2019
17:33:33 +0000
Is Dynavax Technologies Corporation (DVAX) A Good Stock To Buy?
How do we determine whether Dynavax Technologies Corporation (NASDAQ:DVAX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Thu, 09 May 2019
01:23:49 +0000
Dynavax Technologies Corp (DVAX) Q1 2019 Earnings Call Transcript
DVAX earnings call for the period ending March 31, 2019.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This last year I have subscribed to two investment services, ValueForum and a well known income newsletter. ValueForum costs a little over 200 per year. The income newsletter costs about 400 per year. I am up 11% on investments made because I heard about them on ValueForum (of course, I do my own research on everything but the ideas came from ValueForum and there was always some discussion of the pros and cons of each investment on VF). I am down 8% on investments made because I heard about them from the income newsletter. I might also add that I often hear about breaking events immediately on ValueForum and a day or two later the same information is finally available from the newsletter. Hmmm...... which service is the better value?" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2019, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards